2015 Comparative Effectiveness Research Infographic

2015 Comparative Effectiveness Survey

Now in its fifth year, the National Pharmaceutical Council’s annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making.

The stakeholders we surveyed...

  • Government 10%
  • Researchers / Thought Leaders 39%
  • Insurers / Health Plans 7%
  • Employers 10%
  • Business Coalitions 22%
  • Associations 12%

Said CER was important

  • 62% very important
  • 30% somewhat important
  • 7% slightly important
  • 1% not at all important

But its impact on decision-making is still 3-5 years down the road

Stakeholders alo told us which organizations are playing key roles in the CER effort

  • AHRQ 62%
  • NIH 63%
  • PCORI 75%

Key players in setting research standards

  • NIH 50%
  • Academia 50%
  • AHRQ 68%
  • PCORI 77%

Key roles in funding, monitoring research

  • Industry 65%
  • NIH 73%
  • PCORI 81%

Key groups in conducting CER

  • Academia 86%
  • Industry 60%
  • NIH 48%

Key Players in Disseminating CER

  • Academia 60%
  • PCORI 69%
  • AHRQ 78%

For key roles, stakeholders were asked to choose among the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Patient-Centered Outcomes Research Institute (PCORI), academia, private health plans and the biopharmaceutical industry. N=122 for Stakeholders Surveyed. N=115 for Importance of CER. N=114 for Impact of CER in the Past Year and 1 Year; N=115 for the Next 3 Years and Next 5 Years. N=117 for remaining figures.

View the complete survey results and related materials and download our booklet, 2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making at www.npcnow.org/cersurvey15

Embed this infographic on your site

Download the Infographic PDF

2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making PDF